Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Century Therapeutics, Inc. logo

Century Therapeutics, Inc. (IPSC) Stock Ticker

NASDAQ: IPSC · Healthcare · Biotechnology
$1.67-1.18%
USD · as of 2026-09-27 · market cap $144.6M
Open IPSC in TickrDownload for iPhone

IPSC right now

72% of the float is sold short.
Options expect by Oct 6±14.4%
Options expect by Oct 29±29.7%
Priced in for Nov 12 earnings±36.0%
IV rank (30-day)30% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full IPSC picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on IPSC
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Century Therapeutics, Inc.

Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.

IPSC stock facts

Ticker symbolIPSC
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$144.6M
CEOBrent Pfeiffenberger
Employees78
HeadquartersPhiladelphia, PA, US
IPO date2021-06-18
Websitewww.centurytx.com

What you can see for IPSC on Tickr

Live IPSC price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the IPSC report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Century Therapeutics, Inc.?

The ticker symbol for Century Therapeutics, Inc. is IPSC, listed on the NASDAQ Global Select.

What is IPSC?

Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell…

HomeExploreMarketLists
All pages